|
CORPORATE AND SOCIAL
RESPONSIBILITY
GlaxoSmithKline aims to be a valued corporate citizen
wherever it does business.
We make a significant and positive contribution
to society through our medicines, vaccines and healthcare
products. Our products must improve people’s lives to
ensure a profitable and sustainable future for our business.
Understandably, stakeholders - including employees - want
to know how we make this profit.
We publish a separate report on corporate and
social responsibility, including access to medicines in the
developing world, R&D for diseases of the developing world,
preferential pricing arrangements and environmental, health
and safety performance.
COMMUNITY PROGRAMMES
AND CORPORATE DONATIONS
Many of our community programmes are long-term commitments
that help bring about sustainable change. In 2002, we spent
£239 million in support of community programmes, product
donations and charitable contributions.
These activities are focused on disease programmes,
regional community initiatives, education, product donations
and employee involvement. Three of our largest programmes
are major initiatives in public health:
Lymphatic filariasis
The mosquito-borne lymphatic filariasis (LF or elephantiasis)
is one of the world’s most disabling diseases. We are
committed to continuing as an active member of the Global
Alliance to Eliminate Lymphatic Filariasis. In 2002, the fourth
year of the programme, 66 million tablets, worth £8.7
million at wholesale acquisition cost were donated to 31 countries.
HIV/AIDS
Through Positive Action, GlaxoSmithKline works in
partnership with networks of people living with HIV/AIDS,
community groups, international agencies, and nongovernmental
organisations to intensify community responses to HIV/AIDS.
Our programme of HIV education, care and community
support marked its tenth anniversary in 2002. During the year,
Positive Action supported 25 international programmes in partnership
with 22 community-based organisations in 32 countries.
Malaria
In 2002, we launched the African Malaria Partnership
to help combat a disease that kills more than one million
people every year. Three behavioural development programmes
in seven countries will share grants of £1.0 million
over the next three years and will benefit nearly two million
people in malaria-endemic communities.
|
